Thursday, May 9, 2013

Fantasy Sports Betting Boom Gives Investors Several Opportunities

Americans' attendance at sporting events has been steadily increasing over the past decade, but their fantasy participation has been growing at an even quicker rate.

A small player that entered the market is a company called MGT Capital Investments (MGT). The company is primarily engaged in the business of acquiring, developing and monetizing intellectual property rights. On April 22, the company announced that its wholly owned subsidiary, MGT Sports, Inc., has reached an agreement to acquire a controlling interest in FanTD LLC, marking the company's initial venture in the online and mobile gaming and wagering space.

Read More on Seeking Alpha

Wednesday, May 8, 2013

MusclePharm, An American Success Story

As stated in my previous article: "A Closer Look At MusclePharm," the company develops, markets and sells athlete-focused, high quality nutritional supplements primarily to specialty resellers. In this article you'll find new information why MusclePharm is leading the way.

Read More On Seeking Alpha

Adept Technology, A Robotic Opportunity - Part I

'Automation' is the growing phenomenon of human labor being replaced by machinery and robotics. Automation can be positive for businesses by increasing labor productivity, reducing wage costs, increasing profit margins and also filling labor shortages, as has happened in China.
One U.S. company that is a robotic opportunity for investors looking for exposure in the field of automation I am going to describe in this article. The company is called Adept Technology (ADEP).

DelMar Pharmaceuticals: A Small Cap Worth Considering

Investment Thesis
DelMar Pharmaceuticals is a clinical & commercial stage oncology company that has a well-validated lead drug candidate VAL-083, that holds commercial rights to their lead product in China. The management has a history of successful exits: Matrix and Chemgenix.
The company has a lead product candidate called VAL-083. VAL-083 is a bi-functional alkylating agent, with potential antineoplastic activity. VAL-083 crosses the blood brain barrier (BBB) and appears to be selective for tumor cells. This agent alkylates and crosslinks DNA which ultimately leads to a reduction in cancer cell proliferation. In addition, VAL-083 does not show cross-resistance to other conventional chemotherapeutic agents and has a long half-life in the brain.

Read more on Seeking Alpha

Friday, May 3, 2013

Intellectual Property: Hype Or Real Deal?

One of the biggest international business law trends this year is Intellectual Property. Last year's legal battle between Apple (AAPL) and Samsung (SSNLF.PK) was an excellent preview of the major trend to look out for in 2013 - the explosion in the number of international intellectual property disputes.

Intellectual Property - like never before, it's worth fighting for.

A great way investors can seek profit from this trend is looking for companies that focus on Intellectual Property services. I came across three listed companies that could be interesting investments going forward.

Read more on Seeking Alpha

China Investor King Will Be Transferred To Dutch Trader Investor

This blog has another address:

After the weekend the address: is not available anymore.

The blog doesn't focus on US-listed China stocks anymore. Of course if there are opportunities we will let you know.

Wednesday, May 1, 2013

Looking Into The Specialty Pharmacy Sector

In 2012, Americans filled more than 4 billion prescriptions at 62,000 retail, mail, and specialty pharmacies. The largest U.S. pharmacies ranked by total prescription you will find in the table below, some of these companies offer also specialty pharmacy services (CVS Caremark and Express Scripts). We think the specialty pharmacies sector offers a great opportunity for investors that want to stay ahead of the curve.

Read more on Seeking Alpha